Medplus Health Board Meeting Scheduled for May 20 to Approve FY26 Audited Results

Medplus Health Services Ltd announced its board meeting is scheduled for May 20, 2026. The primary agenda is to approve the company's audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. Alongside this, the company has closed its trading window for designated persons, which will remain shut until May 22, 2026.

Investor Focus on Full-Year Performance

The approval of audited financial results is a critical event for shareholders. These finalized figures offer a clear picture of Medplus Health's financial performance, profitability, and growth trajectory over the past fiscal year. Investors will closely examine these numbers to make informed decisions.

Company Expansion and Recent Performance

MedPlus Health Services, a significant player in India's pharmacy retail sector, has been actively expanding its network, aiming to add 600 new stores in FY26. The company added 182 stores in Q3 FY26, bringing its total to over 5,100 outlets. Recent financial reports for Q3 FY26 indicated robust revenue growth, reaching ₹1,806 crore, a 15.67% increase year-on-year. Net profit also rose by 26% to ₹57.8 crore. For the full FY25, consolidated revenue was reported at ₹6,180 crore. Despite this growth, the company navigates competitive intensity, which has led to margin pressures, with operating margins around 8.78% in Q3 FY26. Growth in private label sales offers a partial offset.

Outlook Post-Results Approval

Shareholders and market participants will await the official announcement of the audited full-year financial results. These definitive figures will provide a clear assessment of Medplus Health's profitability and operational efficiency for FY26, potentially refining the outlook from unaudited quarterly reports.

Competitive Landscape

MedPlus operates in a highly competitive market. Apollo Pharmacy is India's largest chain with over 7,000 stores. In the online pharmacy space, Tata 1mg leads with a 31% market share, followed by Reliance Netmeds (15-18% share). PharmEasy's market share has seen a decline.

Key Actions and Investor Watchpoints

Investors will be focused on several key points following this announcement:

• The official declaration of audited standalone and consolidated financial results for FY26.
• Any commentary or guidance from the company regarding future growth strategies, store expansion plans, and efforts to manage margins.
• The re-opening of the trading window on May 23, 2026, which could see increased stock activity once the results are public.